Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE study
Interactions between patients with schizophrenia and psychiatrists or psychiatric nurses vary depending on the care setting, which can influence the acceptance of LAIs. Initial schizophrenia presentation, family support, hospitalizations, trust in HCPs, and logistical challenges may all play a role in patient outcomes and perceptions of LAIs.
Authors
- Ayelet Yaari (ORCID: https://orcid.org/0000-0003-4782-8203)
- Alma Patricia González (ORCID: https://orcid.org/0000-0002-3401-7519)
- Anna S. Levin (ORCID: https://orcid.org/0000-0003-2427-8368)
- Stephan Heres (ORCID: https://orcid.org/0000-0002-1351-003X)
- Mark Suett (ORCID: https://orcid.org/0000-0002-6840-1535)
- Martin Sergerie
- Sigal Kaplan (ORCID: https://orcid.org/0000-0002-3352-8480)
- Kelli R. Franzenburg
- Martha Sajatovic
- Rolf Hansen
- Kameron Sedigh
Institutions
- Global Affairs Canada (CA)
- University Hospitals of Cleveland (US)
- Isar-Amper-Klinikum München-Ost (DE)
- Syneos Health (United States) (US)
- Teva Pharmaceuticals (Israel) (IL)
- Teva Pharmaceuticals (United States) (US)
- TES Global (United Kingdom) (GB)
- Teva Pharmaceuticals (Czechia) (CZ)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3389/fpsyt.2025.1645328
- Citations
- 2
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Teva Pharmaceutical Industries